Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. 2021

Yonghong Liu, and Shirin Strohmeier, and Irene González-Domínguez, and Jessica Tan, and Viviana Simon, and Florian Krammer, and Adolfo García-Sastre, and Peter Palese, and Weina Sun
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Influenza viruses undergo antigenic changes in the immuno-dominant hemagglutinin (HA) head domain, necessitating annual re-formulation of and re-vaccination with seasonal influenza virus vaccines for continuing protection. We previously synthesized mosaic HA (mHA) proteins of influenza B viruses which redirect the immune response towards the immuno-subdominant conserved epitopes of the HA via sequential immunization. As ~90% of current influenza virus vaccines are manufactured using the inactivated virus platform, we generated and sequentially vaccinated mice with inactivated influenza B viruses displaying either the homologous (same B HA backbones) or the heterologous (different B HA backbones) mosaic HAs. Both approaches induced long-lasting and cross-protective antibody responses showing strong antibody-dependent cellular cytotoxicity (ADCC) activity. We believe the B virus mHA vaccine candidates represent a major step towards a universal influenza B virus vaccine.

UI MeSH Term Description Entries
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009976 Orthomyxoviridae Infections Virus diseases caused by the ORTHOMYXOVIRIDAE. Orthomyxovirus Infections,Infections, Orthomyxoviridae,Infections, Orthomyxovirus,Swine Influenza,Infection, Orthomyxoviridae,Infection, Orthomyxovirus,Influenza, Swine,Orthomyxoviridae Infection,Orthomyxovirus Infection
D009981 Influenza B virus Species of the genus BETAINFLUENZAVIRUS that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed. Betainfluenzavirus influenzae,FLUBV,Human Influenza B Virus,Influenza Viruses Type B,Influenza virus type B,Orthomyxoviruses Type B,Influenza B viruses
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D015164 Vaccines, Inactivated Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins. Inactivated Vaccine,Killed Vaccine,Killed Vaccines,Vaccines, Killed,Inactivated Vaccines,Vaccine, Inactivated,Vaccine, Killed
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D019267 Hemagglutinin Glycoproteins, Influenza Virus Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.

Related Publications

Yonghong Liu, and Shirin Strohmeier, and Irene González-Domínguez, and Jessica Tan, and Viviana Simon, and Florian Krammer, and Adolfo García-Sastre, and Peter Palese, and Weina Sun
June 2017, Journal of virology,
Yonghong Liu, and Shirin Strohmeier, and Irene González-Domínguez, and Jessica Tan, and Viviana Simon, and Florian Krammer, and Adolfo García-Sastre, and Peter Palese, and Weina Sun
October 2015, mBio,
Yonghong Liu, and Shirin Strohmeier, and Irene González-Domínguez, and Jessica Tan, and Viviana Simon, and Florian Krammer, and Adolfo García-Sastre, and Peter Palese, and Weina Sun
November 2019, Vaccines,
Yonghong Liu, and Shirin Strohmeier, and Irene González-Domínguez, and Jessica Tan, and Viviana Simon, and Florian Krammer, and Adolfo García-Sastre, and Peter Palese, and Weina Sun
September 2019, Vaccine,
Yonghong Liu, and Shirin Strohmeier, and Irene González-Domínguez, and Jessica Tan, and Viviana Simon, and Florian Krammer, and Adolfo García-Sastre, and Peter Palese, and Weina Sun
January 2016, PloS one,
Yonghong Liu, and Shirin Strohmeier, and Irene González-Domínguez, and Jessica Tan, and Viviana Simon, and Florian Krammer, and Adolfo García-Sastre, and Peter Palese, and Weina Sun
April 2021, Nature,
Yonghong Liu, and Shirin Strohmeier, and Irene González-Domínguez, and Jessica Tan, and Viviana Simon, and Florian Krammer, and Adolfo García-Sastre, and Peter Palese, and Weina Sun
November 2014, Journal of virology,
Yonghong Liu, and Shirin Strohmeier, and Irene González-Domínguez, and Jessica Tan, and Viviana Simon, and Florian Krammer, and Adolfo García-Sastre, and Peter Palese, and Weina Sun
January 2009, Vaccine,
Yonghong Liu, and Shirin Strohmeier, and Irene González-Domínguez, and Jessica Tan, and Viviana Simon, and Florian Krammer, and Adolfo García-Sastre, and Peter Palese, and Weina Sun
April 2019, Viruses,
Yonghong Liu, and Shirin Strohmeier, and Irene González-Domínguez, and Jessica Tan, and Viviana Simon, and Florian Krammer, and Adolfo García-Sastre, and Peter Palese, and Weina Sun
September 2020, Human vaccines & immunotherapeutics,
Copied contents to your clipboard!